For chemical manufacturing companies serving the pharmaceutical sector, benzamidoxime represents a building block whose dual functionality—amide and oxime—opens diverse synthetic pathways. Supplied as the hydrochloride salt (CAS 613-92-3) with purities of 97–98%, this intermediate enables heterocycle formation, catalysis, and prodrug design. Chemical manufacturing companies that maintain consistent quality documentation help medicinal chemists predict reactivity and avoid batch-to-batch variability in multi-step syntheses.
The oxime nitrogen of benzamidoxime exhibits strong nucleophilicity, reacting with electrophiles to form new carbon-nitrogen bonds. Chemical manufacturing companies tracking downstream applications note its role in synthesizing 1,2,4-thiadiazole N-oxides, where benzamidoxime reacts with dichlorodithiazolium chloride to yield the N-oxide as a minor but structurally significant product. Such transformations introduce sulfur-nitrogen heterocycles that appear in antimicrobial and anti-inflammatory pharmacophores, expanding the structural diversity accessible from a single intermediate.
Cyclization with carboxylic acids or aldehydes generates 1,2,4-oxadiazoles, a privileged scaffold in drug discovery. Chemical manufacturing companies supplying benzamidoxime support programs targeting glioblastoma and other cancers, where oxadiazole derivatives demonstrate IC?? values in the low micromolar range against U87 and T98G cell lines. The amidoxime’s ability to undergo O-acylation followed by cyclodehydration makes it a preferred precursor for these five-membered heterocycles.
Base-promoted annulation with terminal alkynes offers a transition-metal-free route to 2,4-disubstituted imidazoles. Chemical manufacturing companies familiar with this chemistry recognize cesium carbonate in DMSO as the optimal system, achieving yields of 55–75%. For chemical manufacturing companies, the absence of palladium or copper catalysts reduces cost and simplifies purification, making this pathway attractive for scale-up of imidazole-based pharmaceutical intermediates.
The amide moiety provides complementary reactivity. Hydrolysis liberates a carboxylic acid or amine, enabling further elaboration into esters or amides. Chemical manufacturing companies should note benzamidoxime’s additional role as a catalyst in peptide synthesis: patent literature reports its use in generating CBz-Lys-NCA-derived compounds, with 1.5 equivalents providing optimal yield without compromising purity. This dual utility—intermediate and catalyst—justifies inventory decisions by chemical manufacturing companies serving both discovery and process chemistry teams.
Prodrug design represents another application domain. Benzamidoxime serves as the model substrate for the mitochondrial amidoxime reducing component (mARC) enzyme system, which reduces N-hydroxylated amidines to amidines in vivo. Chemical manufacturing companies supplying this compound enable formulation scientists to characterize bioactivation rates before committing to animal studies. The established metabolic pathway—predominantly N-reduction with minor O-glucuronidation by UGT1A9—provides a baseline for predicting pharmacokinetics of amidoxime-based prodrugs.
Safety and handling require attention. Benzamidoxime hydrochloride melts at 77°C and exhibits a predicted pKa of 6.85, indicating partial ionization under physiological conditions. Chemical manufacturing companies should advise storage under dry conditions to prevent hydrolysis. For chemical manufacturing companies shipping internationally, compliance with GHS classification and provision of comprehensive safety data sheets supports safe laboratory use and regulatory acceptance.
In summary, benzamidoxime empowers pharmaceutical synthesis through oxadiazole and imidazole construction, catalytic applications, and prodrug design. Its versatility as both a reactive intermediate and a model substrate for metabolic studies makes it valuable across discovery and development phases. Chemical manufacturing companies that supply this compound with documented purity, technical support, and reliable scale-up capabilities contribute materially to the efficiency of heterocycle-focused drug discovery programs.
Comments